IPH 2101 (anti-KIR)
Published: Nov 18, 2010 4:50 pm
| Brand Name: | |
| Generic Name: | |
| Code Name: | IPH 2101 (anti-KIR) |
| Company: | Innate Pharma |
| FDA Clinical Phase: | 1/2 |
Description:
IPH 2101 is a human antibody that helps activate cells of the immune system to destroy cancer cells. Specifically, IPH 2101 activates anti-tumor immune cells, known as natural killer cells, by blocking KIR inhibitory receptors on the surface of the immune cells. IPH 2101 is being studied in patients with smoldering myeloma, multiple myeloma, and acute myeloid leukemia.
Clinical Trials:
For a list of clinical trials studying IPH 2101 for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official website for IPH2101: http://www.innate-pharma.com/therapeutic-area/iph-2101.
Related Articles:
- Getting To Know: Tiragolumab
- Could A Decades-Old Antibiotic Have Anti-Myeloma Activity?
- Dr. Christoph Driessen On Nelfinavir In The Treatment Of Multiple Myeloma
- U.S. FDA Okays First Clinical Trial Of An Allogeneic CAR T-Cell Therapy For Multiple Myeloma
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma
